CL2012002173A1 - Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica. - Google Patents

Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.

Info

Publication number
CL2012002173A1
CL2012002173A1 CL2012002173A CL2012002173A CL2012002173A1 CL 2012002173 A1 CL2012002173 A1 CL 2012002173A1 CL 2012002173 A CL2012002173 A CL 2012002173A CL 2012002173 A CL2012002173 A CL 2012002173A CL 2012002173 A1 CL2012002173 A1 CL 2012002173A1
Authority
CL
Chile
Prior art keywords
sgc
stimulator
activator
treatment
combination
Prior art date
Application number
CL2012002173A
Other languages
English (en)
Inventor
Peter Sandner
Degenfeld Georges Von
Johannes Peter Stasch
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002173(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CL2012002173A1 publication Critical patent/CL2012002173A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)

Abstract

Combinación de al menos un estimulador o activador de la Sgc con un inhibidor de la PDE5; formulación farmacéutica; y uso para el tratamiento de la fibrosis quística.
CL2012002173A 2010-02-05 2012-08-03 Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica. CL2012002173A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10152727 2010-02-05

Publications (1)

Publication Number Publication Date
CL2012002173A1 true CL2012002173A1 (es) 2013-05-17

Family

ID=43759663

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002173A CL2012002173A1 (es) 2010-02-05 2012-08-03 Combinacion de al menos un estimulador o activador de la sgc con un inhibidor de la pde5; formulacion farmaceutica; y uso para el tratamiento de la fibrosis quistica.

Country Status (33)

Country Link
US (1) US20130035340A1 (es)
EP (1) EP2531187B1 (es)
JP (2) JP6143461B2 (es)
KR (1) KR101793304B1 (es)
CN (3) CN107929271A (es)
AU (1) AU2011212521B2 (es)
BR (1) BR112012019666A2 (es)
CA (1) CA2788969C (es)
CL (1) CL2012002173A1 (es)
CR (1) CR20120408A (es)
CY (1) CY1116878T1 (es)
DK (1) DK2531187T3 (es)
EA (1) EA025177B1 (es)
ES (1) ES2548394T3 (es)
HK (1) HK1212892A1 (es)
HR (1) HRP20151187T1 (es)
HU (1) HUE028008T2 (es)
IL (1) IL221012B (es)
MA (1) MA33984B1 (es)
MX (1) MX342944B (es)
MY (2) MY159697A (es)
NZ (1) NZ601612A (es)
PH (1) PH12012501587A1 (es)
PL (1) PL2531187T3 (es)
PT (1) PT2531187E (es)
RS (1) RS54336B1 (es)
SG (1) SG182819A1 (es)
SI (1) SI2531187T1 (es)
SM (1) SMT201500286B (es)
TN (1) TN2012000397A1 (es)
UA (1) UA112962C2 (es)
WO (1) WO2011095534A1 (es)
ZA (1) ZA201205532B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012019666A2 (pt) * 2010-02-05 2017-06-20 Bayer Ip Gmbh estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística
ES2549979T3 (es) 2010-05-26 2015-11-03 Adverio Pharma Gmbh El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
CA2803688A1 (en) * 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
MX338887B (es) * 2012-09-07 2016-05-04 Boehringer Ingelheim Int Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015011086A1 (en) * 2013-07-25 2015-01-29 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
JP2016540017A (ja) 2013-12-11 2016-12-22 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激物質
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
AU2015292833B2 (en) 2014-07-22 2019-11-28 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
US10844064B2 (en) 2014-09-17 2020-11-24 Cyclerion Therapeutics, Inc. sGC stimulators
EP3194382B1 (en) 2014-09-17 2021-09-08 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sgc stimulators
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CN108473470A (zh) 2015-12-18 2018-08-31 诺华股份有限公司 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
SG10202106949XA (en) 2016-11-18 2021-07-29 Cystic Fibrosis Found Pyrrolopyrimidines as cftr potentiators
CN110300589B (zh) 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
CN110305125B (zh) * 2019-06-06 2021-09-03 山东新华制药股份有限公司 5-嘧啶-6-氧-吡唑并吡啶类衍生物及其制备方法和应用
KR20250088783A (ko) 2022-11-04 2025-06-17 베링거 인겔하임 인터내셔날 게엠베하 전신 경화증을 치료하기 위한 가용성 구아닐레이트 사이클라제 활성제

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
CZ302691B6 (cs) * 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) * 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047946A1 (de) * 2005-10-06 2007-05-03 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten
US20080081816A1 (en) * 2006-10-03 2008-04-03 Kaohsiung Medical University Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3
BRPI0811581A2 (pt) * 2007-05-12 2014-12-09 Bayer Schering Pharma Ag Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
CN101939053A (zh) 2007-09-06 2011-01-05 默沙东公司 可溶性的鸟苷酸环化酶活化剂
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
PE20091258A1 (es) 2007-12-03 2009-09-12 Smithkline Beecham Corp Derivados de piridina como activadores de la guanilato ciclasa soluble
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
ES2559840T3 (es) * 2008-06-04 2016-02-16 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
BR112012019666A2 (pt) * 2010-02-05 2017-06-20 Bayer Ip Gmbh estimuladores da sgc ou ativadores da sgc individualmente e em combinação com inibidores da pde5 para o tratamento de fibrose cística

Also Published As

Publication number Publication date
SMT201500286B (it) 2016-01-08
CR20120408A (es) 2013-02-12
UA112962C2 (uk) 2016-11-25
HUE028008T2 (en) 2016-11-28
MY160856A (en) 2017-03-31
RS54336B1 (sr) 2016-02-29
EP2531187B1 (en) 2015-08-12
SG182819A1 (en) 2012-09-27
AU2011212521A1 (en) 2012-08-16
IL221012B (en) 2018-01-31
EA025177B1 (ru) 2016-11-30
WO2011095534A1 (en) 2011-08-11
SI2531187T1 (sl) 2016-01-29
DK2531187T3 (en) 2015-11-09
EP2531187A1 (en) 2012-12-12
CN102770133A (zh) 2012-11-07
CN104800219A (zh) 2015-07-29
JP6270907B2 (ja) 2018-01-31
HRP20151187T1 (hr) 2015-12-04
MX2012009011A (es) 2012-09-07
AU2011212521B2 (en) 2015-11-19
NZ601612A (en) 2014-08-29
MY159697A (en) 2017-01-13
JP2013518851A (ja) 2013-05-23
CA2788969A1 (en) 2011-08-11
ZA201205532B (en) 2014-12-23
PH12012501587A1 (en) 2020-10-19
KR20120125276A (ko) 2012-11-14
US20130035340A1 (en) 2013-02-07
ES2548394T3 (es) 2015-10-16
PL2531187T3 (pl) 2016-01-29
TN2012000397A1 (en) 2014-01-30
MA33984B1 (fr) 2013-02-01
CA2788969C (en) 2017-11-21
CN107929271A (zh) 2018-04-20
PT2531187E (pt) 2015-10-20
EA201290702A1 (ru) 2013-02-28
HK1212892A1 (zh) 2016-06-24
CY1116878T1 (el) 2017-04-05
MX342944B (es) 2016-10-18
KR101793304B1 (ko) 2017-11-02
JP2016155857A (ja) 2016-09-01
BR112012019666A2 (pt) 2017-06-20
JP6143461B2 (ja) 2017-06-07
IL221012A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2013003313A1 (es) Compuestos derivados de 2,4-diaminoquinazolinas, sales o solvatos farmacéuticamente aceptables; composición farmacéutica que los comprende; y uso en el tratamiento de un trastorno en el que interviene la modulación de tlr7 y/o tlr8.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
MX388787B (es) El uso de amisulpride como un anti-emético.
BR112012020719A2 (pt) formulação herbicida método de tratamento de plantas com herbicida método de aumento da eficácia de uma formulação herbicida, e, uso de uma composição
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2011001712A1 (es) Combinacion de 0,1 a 1 mg de al menos un estimulador de sgc seleccionado de un grupo definido con 2,5 a 20 mg de un inhibidor de pde5 seleccionado de otro grupo; formulacion farmaceutica que la comprende y uso en el tratamiento de la disfuncion sexual masculina.
EP2594270A3 (en) The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
BR112014021068A8 (pt) inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
CO6700840A2 (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1